Alkylphenyl benzopyrans

ABSTRACT

Alkylphenyl benzopyrans represented by the formula   WHEREIN N IS 1 OR 2; EACH R and R1 are the same or different members of the group consisting of hydrogen or loweralkyl; R2 is loweralkyl; R3 is hydrogen; Y is a straight or branched chain alkylene group having from one to ten carbon atoms; and each R4 and R5 and R6 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl and Z is C or N and the pharmaceutically acceptable salts thereof.

United States Patent 1 Winn et a].

[ Aug. 26, 1975 ALKYLPHENYL BENZOPYRANS [75] Inventors: Martin Winn, Deerfield; Kathleen Riley Lynn, Gumff; Yvonne Connolly Martin, Waukegan, all of ill.

[73] Assignee: Abbott Laboratories, North Chicago, Ill.

[22] Filed: Feb. 13, 1974 [21] Appl. No.2 442,034

Related U.S. Application Data [63] Continuation-impart of Ser. No. 345,944, April 2,

1973, abandoned.

[52] U.S. Cl.... 260/345.3; 260/290 HL; 260/297 R; 260/297 T; 260/343.5; 260/590; 260/625;

[51] Int. Cl. C07D 307/83 [58] Field of Search.... 260/3453 [56] References Cited UNITED STATES PATENTS 2,509,386 5/1950 Adams 260/3453 3,639,426 2/1972 Razdan et a]. 260/3453 3,799,946 3/1974 Loev 260/3453 Primary Examiner-Howard T. Mars Assistant ExaminerNicky Chan Attorney, Agent, or FirmVincent AnMallare; Robert L. Niblack [57] ABSTRACT Alkylphenyl benzopyrans represented by the formula wherein n is l or 2; each R and R are the same or different members of the group consisting of hydrogen or loweralkyl; R is loweralkyl', R is hydrogen; Y is a straight or branched chain alkylene group having from one to ten carbon atoms; and each R and R and R are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl and Z is C or N and the pharmaceutically acceptable salts thereof.

6 Claims, No Drawings ALKYLPHENYL BENZOPYRANS REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part application of US. Ser. No. 345,944, filed Apr. 2, 1973, now abandoned.

DETAILED DESCRIPTION OF THE INVENTION This invention relates to novel benzopyrans and more particularly relates to benzopyrans having an alkylphenyl side chain and having more selective pharmacological actions than the corresponding natural products.

While there are a number of currently available analgesic products, the search for improved analgesic agents has continued for a number of reasons. Aspirin, one of the most effective analgesic agents, does not provide sufficient analgesia to control severe pain such as postoperative pain, pain following certain dental procedures or encountered with toothaches, pain associated with cancer, and the like. A further problem with aspirin is the side effects, particularly the gastrointestinal effects, its ulcergenicity, and the sensitivity which a number of people develop to it. A number of the more potent analgesic agents such as codiene, Demerol and morphine have a high addiction liability and are thus classified as narcotics. While one nonaddieting analgesic agent, d-propoxyphene HCl (Darvon) is available, Darvon does not produce sufficient analgesia to be useful in severe pain states. Darvon further seems to be specific for certain types of pain, and is not effective in all individuals. Therefore, the search for improved, potent, nonaddicting analgesic agents has continued. The present invention provides such agents.

It is also commonly recognized that patients suffering from severe pain, or suffering from pain for any length of time, tend to become anxious and depressed. The compounds of this invention additionally exhibit activity as anti-anxiety agents. This combination of analgesia and anti-anxiety activities makes the compounds of this invention particularly useful as a therapeutic group. In addition, the compounds are useful as antidiarrheal agents, which also makes them useful in the treatment of anxiety, which is often accompanied by diarrhea.

The compounds of this invention are represented by the formula wherein, in the C ring, a bond, followed by a dotted line indicates the double bond can appear at various positions in the ring, wherein n is l or 2; R and R, each are the same or different members of the group consisting of hydrogen or loweralkyl; R is loweralkyl; R is hydro gen; Y is a straight or branched chain alkylene group having from one to ten carbon atoms; and each R and R and R are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl and 2 is C or N; and the pharmaceutically acceptable salts thereof.

The term loweralkyF as used herein, refers to straight or branched chain alkyl radicals of from I to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropy], n-butyl, sec-butyl, n-pentyl, neo-pentyl, nhexyl, and the like.

Halo" includes chloro, fluoro, bromo and iodo.

The term pharmaceutically acceptable salts" includes cationic salts such as the sodium, potassium, calcium, barium, aluminum, ammonium or substituted ammonium salts.

When, for example, n is I, the compounds are represented by formulae III, IV and V, wherein the side chain is designated as R III OR R1 3 when n is 2, the preferred compounds are reprel5 :nted by formulae Y], VII and VI".

VII

VIII

ntermediates made in preparing the compounds of (15 invention have the following structural formulae:

wherein n is l or 2; R and R, are hydrogen or methyl.

The compounds of this invention are useful as analgesic agents at dosages of from 0.01 to 25.0 mg./kg. of body weight daily. They may be given via oral, parenteral or intravenous administration. The presently pre ferred compound, 3-(4-fluorophenyll -methylbutyl l hydroxy-6,6,9-trimethyl-7,8 ,9, lO-tetrahydro-GH- dibenzo[b,d]pyran, has an oral ED of 6.1 in the mouse writhing test for analgesia, [Whittle, Brit. J. PharmacoL, 22 296 1964)], (codeine has an oral ED of 15.6 mg./kg. in the mouse writhing test), an oral ED of 5.9 mgJkg. in the rat tail flick test [Harris, et al., J. Pharm. Exp. Ther., I69 I? (1969)] and an oral ED of 0.94 mg./kg. in the hot plate test.

In addition to their use as analgesic agents, the compounds are useful as mild tranquilizers at dosages of from 0.01 to 20 mg./kg. of body weight daily. Since many patients suffering from pain are anxious and apprehensive, the compounds of this invention are particularly useful as analgesic agents. The compounds further appear to produce analgesia and mild tranquilization without sedative or sedative-hypnotic effect. thus enabling the patients to carry out their normal activities while taking a compound of this invention. The compounds are also useful as antidiarrheal agents at dosages of from 0.0l to 20 mg./kg. of body weight daily.

Generally speaking, the compounds of this invention wherein R is hydrogen can be prepared according to the following reaction scheme:

RII I Followed by I R C "R' steps & 6 CH H0 n A of scheme 1 3 Q ll 1| C-CH R' CH =CH \I Q C-(lII-ICH CH R CH3) c11 0 1) RMgBr 2) H 3) Hr V CH OH followed by CH 0 Cll-CHCH CH steps 5 and 6 C'Ill-(IHCH2CH2 of scheme 1 I 3 R R HO R R The following examples further illustrate the present EXAMPLE 2 invention. in these preparations a mixture is obtained with structures Vll or lll predominating, but also containing approximately 5 to percent of V] or IV.

EXAMPLE 1 Preparation of 2-( 3 ,S-Dimethoxyphenyl )-5-(4-Fluorophenyl )Pentane A solution of 77 g. of 3-(4-fluorophenyl)propylbromide in 300 ml. of ether was added dropwise over a two hour period to a refluxing solution of 10 g. of magnesium in 100 ml. of ether. The reaction mixture was refluxed for an additional minutes after the addition was completed. A solution of 68 g. of 3,5- dimethoxyacetophenone in 100 ml. of ether was then added dropwise to the reaction and the reaction mixture was refluxed for [V2 hours. To the reaction was added 300 m]. of a saturated ammonium chloride solution dropwise with stirring. The layers were separated and the aqueous layer extracted with ether. The ether extract was dried over magnesium sulfate and the ether removed in vacuo to give an oil. An additional 1 l 1.7 g. of 3(4-fluorophenyl)propylbromide was reacted with 3,S-dimethoxyacetophenone in the above manner. The products from both runs were hydrogenated in ethanoll-lCl using palladium as the catalyst. The solvents and catalyst were removed and the crude material distilled to yield 169.0 g. of 2(3,5-dimethoxyphenyl)-5-(4- fluorophenylJpentane, b.p. 145155/0.05 mmHg.

Analysis Calcd. for C H O Fz C, 75.60; H, 7.69. Found: C, 75.87; H, 7.98.

Preparation of 2-( 3 ,S-Dihydroxyphenyl )-5-( 4-Fluorophenyl )Pentane Fifty grams of the above-prepared 2-(3,5 dimethoxyphenyl)-5-(4-fluorophenyl)pentane, 450 ml. of acetic acid and 180 ml. of 48% l-lBr in water were mixed. While cooling, the mixture was saturated with hydrogen bromide gas (approximately /2 hour). The reaction was placed in. an 87 bath and stirred for 17 hours. The reaction was then concentrated in vacuo and the residue neutralized with K CO and NaHCO extracted with ether, treated with charcoal and MgSO and filtered to yield 45 g. of 2-(3,5-dihydroxyphenyl)- 5-(4-fluorophenyl)pentane as a brown oil which distills at l/0.0l mmHg.

Analysis Calcd. for C H O F: C, 74.20; H. 6.98. Found: C, 73.56; H, 7.04.

EXAMPLE 3 Preparation of 3-( 4-p-Fluorophenyll -Methylbuty] l -Hydroxy-6,6.9- Trimethyl-7,8,9. l 0-Tetrahydro-6H- Dibenzo[ b,d]Pyran Fourteen grams of the above-prepared 243.5- dihydroxyphenyl)-5-(4-fluorophenyl)pentane. l l g. of ethyl, 4-methyl-Z-cyclohexanonel-carboxylate, 60 ml. of benzene and 3.6 ml. of POC] were stirred and refluxed for four hours and Stirred at room temperature for 12 hours. The reaction was poured into water and sodium bicarbonate, extracted with ether, dried over magnesium sulfate and concentrated to an oil. The oil was extracted with pentane to remove the unreacted keto ester. The oil was crystallized from acetonitrile to give 3(4-p-fluorophenyl-l-methylbutyl)-1-hydroxy9- methyl-7,8,9,10-tetrahydro-6H-dibenzo[b,dlpyran- 6-one, m.p. 127 129C.

The above pyrone was then dissolved in 80 ml. of ether and added to a methyl magnesium bromide solution prepared from 13 g. of magnesium and 60 g. of methyl bromide in 350 ml. of ether. After refluxing 16 hours, the reaction was worked up with saturated aqueous ammonium chloride solution. The ether layer was separated, concentrated to dryness and the residue was dissolved in 300 ml. of benzene. To the benzene solution was added 0.05 g of TosOH and the reaction was refluxed for two hours, passing the condensing liquid through 4A molecular sieves. The benzene layer was extracted with sodium bicarbonate in water, concentrated to dryness and dissolved in 500 ml. of pentane. Charcoal was added to the pentane solution and the solution was filtered. The product was then chromato graphed on a Florosil activated aluminum magnesium silicate 42 mm X 30 inch column and eluted with 95% pet ether and 5% ethyl ether to yield 10.4 g. of product as a colorless gum.

Analysis Calcd. for C -,-H FO C, 79.20; H, 8.18. Found: C, 79.36; H, 8.50.

EXAMPLE 4 Preparation of 1-Hydroxy-3-( 4-Phenyll -Methylbutyl )-6,6,9- Trimethyl-7,8,9, l0-Tetrahydro-6H- Dibenzo[ b,d Pyran EXAMPLE 5 Preparation of 7-( 4-p-Fluorophenyll -Methylbutyl)-9Hydroxy-4- Oxo-l ,2,3 ,4-Tetrahydrocyclopenta[c ][l Benzopyrane Twenty-two grams of 5-( l-methyl-4-p-fluorophenyl butyl) resorcinol, 80 ml. of benzene, 6 ml. of POCl 1 drop of water and 13.0 g. of 2-carbethoxycyclopentanone were refluxed for eight hours and then stirred at room temperature for eight hours. The solution was concentrated in vacuo and the residue taken up in ether and neutralized with potassium bicarbonate solution. The organic phase was dried over MgSO, and concentrated. The residue was crystallized from CH -,CN to yield 156 g. of 7-(4-p-fluorophenyll -methy1butyl hydroxy-4-oxo-1,2,3,4-tctrahydrocyclopenta[c][l]bcnzopyran, m.p. l33l35C.

Analysis Calcd. for C -,H O,-,F: C, 75.50: H, 6.33. Found: C, 75.15; H, 6.21.

EXAMPLE 6 Preparation of 4,4-Dimethyl-7-( 4-p-Fluorophenyl l -Methylbutyl )-9- Hydroxy- 1 ,2,3 ,4-Tetrahydrocyclopenta[c] [1]Benzopyran A solution of 15 g. of the above-prepared pyrone in 30 ml. of ether and 50 ml. of benzene were added slowly to a solution of CH MgBr (0.423 mole) in 250 ml. of ether. The reaction was refluxed for 16 hours, and then 500 ml. of a saturated NH C1 solution was added slowly. The ether layer was separated, dried over MgSO and concentrated. The residue was dissolved in pet ether, decolorized with charcoal and chromatographed on a Florosil activated aluminum magnesium silicate 31 mm X 30 inch column to yield 10.9 g. of product as a pale yellow oil.

Analysis Calcd. for C ,,H O F: C, 78.80; H, 7.70. Found: C, 78.80; H, 7.84.

EXAMPLE 7 1-Hydroxy3(4-p-Methy1pheny1-1Methylbutyl)- 6,6,9-Trimethyl-7,8,9, 1 O-Tetrahydro-GH- Dibenzo[b,d]Pyran By the method of Example 1,3-( 4- methylphenyl)propyl bromide was converted into 2- (3,5-dimethoxyphenyl)5-(4-methylphenyl)pentane, b.p. 170-l75/0.6 mmHg.

Analysis Calcd. for C H O C, 80.49; H, 8.78. Found: C, 80.31; H, 9.14.

This compound was converted to the resorcinol by the procedure of Example 2 and then to the desired product by the method of Example 3. The intermediate pyrone had m.p. 133 135.

Analysis Calcd. for C H O C, 79.96; H, 7.74. Found: C, 80.34; H, 8.00.

The final product was a colorless gum.

Analysis Calcd. for C H o z C, 83.12; H, 8.97. Found: C, 83.08; H, 9.10.

EXAMPLE 8 l-Hydroxy-3-(5-p-Fluoropheny1-1-Methylpenty1)- 6,6,9-Trimethyl-7,8 ,9,10-Tetra.hydro-6H- Dibenzo[b,d]Pyran By the method of Example 1, 4-(4- fluorophenyhbutyl chloride was converted to 2-(3,5- dimethoxyphenyl)-6-(4-fluorophenyl)hexane, hp 1 55160/0.3mmHg.

Analysis Calcd. for C H FO C, 75.95; H, 7.96. Found: C, 76.26; H, 7.93.

This compound was converted to the resorcinol by the procedure of Example 2 and then to the desired product by the method of Example 3. The intermediate pyrone had m.p. 146 147.

Analysis Calcd. for c H FO- z C, 76.44; H, 7.15. Found: C, 75.83; H, 7.14.

The final product was a colorless gum.

Analysis Calcd. for C ,,H;, FO C, 79.58; H, 8.34. Found: C, 79.65; H, 8.60.

EXAMPLE 9 l-Hydroxy-3-( ip-Fluorophenylpentyl )-6,6,9

Trimethyl-7,8,9, l 0-Tetrahydro-6H- Dibenzo[b,d ]Pyran By the method of Example 4, (4-fluorophenyl)butyl chloride and 3,S-dimethoxybenzaldehyde were converted to 1-(3,S-dimethoxyphenyl)-5-(4- fluorophenyl)pentane.

This compound was converted to the resorcinol by the procedure of Example 2 and then to the desired product by the method of Example 3. The intermediate pyrone had m.p. 132 133.

Analysis Calcd. for C H F C, 76.11; H, 6.89. Found: C, 75.39; H, 6.85.

The final product was a colorless gum.

Analysis Calcd. for C H FO C, 79.37; H, 8.14. Found: C, 78.76; H, 8.17.

EXAMPLE 10 2-( 3 ,S-Dimethoxyphenyl )-3 -Methyl--( p- F1uoropheny1)Pentane 3,5-Dimethoxy propiophenone (52.0 g.) was added to a suspension prepared from 13.9 g. 57% sodium hydride in mineral oil (which had been freed of mineral oil by washing with toluene) and 130 ml. toluene. The resulting mixture was refluxed 30 minutes, 51 g. of 2-(p-fluorophenyl)ethy1 bromide added and refluxed 2 /2 hours. The mixture was worked up with water and HCl and the product distilled to give 66.4 g. 1-(3,5- dimethoxyphenyl)-2-methyl-4-(p-fluorophenyl l butanone b.p. 160175/0.3mmHg. This ketone in 300 ml. ether was treated with 130 ml. of 3 molar methyl magnesium bromide in ether and worked up with ammonium chloride to give 71.0 g. 2-(3,5- dimethoxypheny1)-3-methyl-S-(p-fluorophenyl )-2- pentanol. This alcohol was hydrogenated in acetic acid containing 2m1. H 80 using palladium catalyst to give 55.0 g. of desired compound, b.p. 150155/0.3mmHg. Gas chromatography showed two isomers of ratio 63/37.

Analysis Calcd. for C H FO C, 75.95; H, 7.96. Found: C, 76.04; H, 8.22.

EXAMPLE 1 1 1-Hydroxy-3-(4-p-F1uoropheny1-1,2-Dimethy1butyl)- 6,6,9-Trimethyl-7 ,8,9, 1 0-Tetrahydro-6H- Dibenzol b,d Pyran The compound of Example 10 was converted to the resorcinol by the procedure of Example 2 and then to the desired product by the method of Example 3. The intermediate pyrone was not crystallized. The final product was a colorless gum.

Analysis Calcd. for C H;,,FO C, 79.58; H, 8.34. Found C, 78.81; H, 8.45.

EXAMPLE 12 2'( 3 ,S-Dimethoxyphenyl )-3-Methy1-6-(4- F1uorophenyl)Hexane 3,5-Dimethoxy propiophenone, 3-(4- fluoropheny1)propyl bromide and methyl magnesium bromide were used to prepare the desired compound as described in Example 10. The product had b.p. l70180/0.5mmHg. Gas chromatography showed two isomers in a 62/38 ratio.

EXAMPLE 13 1-Hydroxy-3-(5-p-F1uorophenyl-1,2-Dimethylpentyl)- 6,6,9-Trimethyl-7,8,9, 1 U-Tetrahydro-SH- Dibenzol b,d lPyran The compound of Example 1 1 was converted to the resorcinol by the procedure of Example 2 and then to the desired product by the method of Example 3. The intermediate pyrone had m.p. 116 117.

Analysis Calcd. for C H FO C, 76.75; H, 7.51. Found: C, 76.72; H, 7.51.

The final product was a colorless gum.

Analysis Calcd. for C H FO C, 79.77; H, 8.54. Found: C, 79.49; H, 8.80.

EXAMPLE 14 1'( 3,5-Dimethoxypheny1)-2-Methy1-4(4-Pyridy1)-1- Butanone EXAMPLE 15 2-( 3,5-Dimethoxyphenyl )-3Methy1-5-(4- Pyridy1)Pentane The above ketone was treated with methyl magnesium bromide and the resulting alcohol hydrogenated in a manner similar to that described in Example 10. The product had hp 180 185/0.3mmHg.

Analysis Calcd. for C H NO C, 76.22; H, 8.42; N, 4.68. Found: C, 75.97; H, 8.40; N, 4.68.

EXAMPLE 1 6 2( 3,5-Dihydroxyphenyl)-3-Methy1-5-( 4- Pyridyl)Pentane The compound of Example 15 (22.0 g.), 220 ml. acetic acid and ml. 48% HBr was saturated with HBr gas and kept at 90 for 18 hours. Solvent was concentrated in vacuo and residue treated with dilute NaOH and NaHCO to get a solid which was crystallized from dimethoxyethane and ether. Yield 19.9 g., m.p. 1 18 122.

Analysis Calcd. for C,,H,,N0,; C, 75.24; H, 7.80; N, 5.16. Found: C, 74.35; H, 7.97; N, 5.11.

EXAMPLE 17 l-Hydroxy-3[4-( 4-Pyridyl)-l ,2-Dimethylbutyll-9- Methyl-6-Oxo-7,8 ,9,10Tetrahydro-6H- Dibenzo[b,d ]Pyran The compound of Example 16 (9.10 g.) was dissolved in 20 ml. methanesulfonic acid containing 14.0 g. POCL, and 7.70 g. ethyl, 4-methyl-2-cyclohexanonel-carboxylate and stirred four days at room temperature. Then water and KHCO were added yielding an oil which was crystallized from acetonitrile giving 7.72 g. of desired product, m.p. 163 165.

Analysis Calcd. for C ,,H NO C, 76.69; H, 7.47; N, 3.58. Found: C, 76.39; H, 7.56; N, 3.72.

EXAMPLE 18 1-Hydroxy-3[4-(4-Pyridyl)-1,2-Dimethylbutyl]'6,6,9- Trimethy1-7,8,9,10-Tetrahydro-6H- Dibenzol b.d lPyran l2.2 g. of the pyrone of Example l7 was added portionwise to a solution of 105 ml. of 3 molar methyl magnesium bromide in tetrahydrofuran and refluxed two hours. The solution was cooled and worked up with saturated ammonium chloride solution. The tetrahydrofuran was removed in vacuo and replaced with chloroform. Hydrogen bromide gas was bubbled in and the sulution boiled 15 minutes. The solution was neutralized with KHCQ', and chromatographed on Florosil eluting with 50% ether, 50% cyclohexane, giving 5.09 g. yellow gum.

Analysis Calcd. for C H NO C, 79.31; H, 9.17; N, 3.l9. Found: C, 79.96; H, 8.70; N, 3.45.

(NMR shows traces of ethyl ether.)

EXAMPLE l9 l-Hydroxy-3-( 3-pFluorophenyll Methylbutyl )-6,6,9- Trimethyl-7 ,8,9 l O-Tetrahydro-6H- Dibenzo[b,dlPyran By the method of Example 1, 2-(4- fluorophenyhethyl bromide was converted into 2-(3,5- dimethoxypheny])-4-(4-fluorophenyl) butane, b.p. l45-l 5510.3mmHg.

Analysis Calcd. for C I- 1 C, 75.0l; H, 7.34. Found: C, 75.09; H, 7.54.

The compound was converted to resorcinol by the procedure of Example 2 and then to the desired product by the method of Example 3. The intermediate pyrone had m.p. l48l50.

Analysis Calcd. for C H FO C, 75.85; H, 6.63.

Found: C, 76.69; H, 6.81.

The final product was a colorless oil.

Analysis Calcd. for C H ,FO C, 79.10; H, 7.93. Found: C, 79.14; H 7.85.

EXAMPLE 20 l-Hydr0xy-3-( 4-p-Fluorophenyll -methylbutyl )-6,6,9- Trimethyl-6a,7,8,9, l 0, a Hexahydro-6H-Dibenzo b,d Pyran l-Hydroxy-3-( 4-p-fluorophenyll -methylbutyl 6,6,9-trimethyl-7,8,9, l0-tetrahydro-6H- dibenzo[b,d]pyran was dissolved in ethanol and hydrogenated with 5% palladium on charcoal as catalyst. After one equivalent of hydrogen was absorbed, the catalyst was removed and the solution concentrated to give the desired product.

EXAMPLE 21 4,4-Dimethyl-7-( 4-p-Fluorophenyll -Methylbutyl )-9- Hydroxy- 1,2,3 ,3a,4,9b-Hexahydrocyclopenta[c l- ]Benzopyran 4,4-Dimethyl-7-( 4-p-fluorophenyll -methylbutyl )-9- hydroxyl ,2.3,4-tetrahydrocyclopenta[c l ]benzopyran was hydrogenated as described in Example 20 to give the desired product as a colorless oil.

EXAMPLE 22 4,4-Dimethyl'7[ 5-(4 Chloro-3- Trifluoromethylphenyl l ,2-Dimethylpentyl1-9- Hydroxy-l ,2,3,4-Tetrahydrocyclopenta[c][llBenzopyran 4-Chloro-3-trifluoromethylaniline was converted to the diazonium salt with sodium nitrite and sulfuric acid and this was reacted with acrylic acid (the Meerwein reaction) to give 4-chloro-3-trifluoromethylcinnamic acid. This acid was hydrogenated, reduced with lithium aluminum hydride to the alcohol and reacted with phosphorus tribromide to give 3-(4-chloro-3-tri fluoromethyhpropyl bromide. This bromide was converted into 2-(3,5-dimethoxyphenyl)-3-methyl-6-(4- chloro-3-trifluoromethyl)hexane by the method described in Example 10. This compound was converted to the resorcinol by the procedure of Example 2 and this reacted with 2-carbethoxycyclopentanone as in Example 5 and with methyl magnesium bromide as in Example 6 to give the desired product.

EXAMPLE 23 l,4,4-Trimethyl-7[4-( 2,6-Dichloro-4-Methylphenyl l-Methylbutyl]-9-Hydroxy-l ,2,3,4 Te trahydrocyclo penta[ c] [l]Benzopyrar1 2,6-Dichloro-4-methylaniline was converted to 3- (2,6-dichloro-4-methylphenyl)propylbromide by using the method described in the first half of Example 22. This was converted to 2-(3,5-dimethoxyphenyl)-5- (2,6-dichloro-4-methylphenyl) pentane by the method of Example I. This compound was converted to the resorcinol by the procedure of Example 2 and this was reacted with 2-carbethoxy-5-methylcyclopentanone by the method of Example 5 and with methyl magnesium bromide as in Example 6 to give the desired product.

EXAMPLE 24 l-Hydroxy-3-( 4-p-[sopropylphenyll -Methylbutyl- 6,6, l O-Trimethyl-7,8,9, l0-Tetrahydro-6H- Dibenzo[ b,d]Pyran 4-lsopropyl benzaldehyde and malonic acid were converted to 4-isopropylcinnamic acid and then to 3-(4-isopropylphenyl)propyl bromide using in this order the following reagents: 1) hydrogen, 2) lithium aluminum hydride, 3) phosphorus tribomide. This was converted to 5-( 4-p-isopropylphenyl )-2-( 3,5- dimethoxyphenyl)pentane by the method of Example 1. This compound was converted to the resorcinol by the procedure of Example 2 and this was reacted with Z-carbethoxy-6-methylcyclohexanone and then with methylmagnesium bromide by the method of Example 2 to give the desired product.

EXAMPLE 25 l-Hydroxy-3 6-( 2,4,6-Trifluorophenyl l .2- Dimethylheptyl -6,6,9,9-Tetramethyl-7 ,8 ,9 l O- Tetrahydro-6H-Dibenzo[ b,d Pyran 2,4,6-Trifluoroaniline is converted to 2,4,6-trifluorocinnamic acid via the diazonium salt and acrylic acid. This was converted into 3-(2,4,6-trifluorophenyl)propyl bromide by using the method described in the first half of Example 22. This bromide was reacted with l) magnesium, 2) ethylene oxide and 3) phosphorus tribromide to give 5-(2,4,6-trifluorophenyl)pentylbromide. This bromide was converted to 243.5- dimethoxyphenyl)-3-methyl-8-(2,4,6-trifluorophenyl) octane by the method described in Example 10. This compound was converted to the resorcinol by the procedure of Example 2 and then reacted with 2- carbethoxy-S,S-dimethylcyclohexanone and then with methylmagnesium bromide by the method of Example 2 to give the desired product.

The present invention includes within its scope phariaceutical compositions comprising, as an active inredient, at least one of the compounds of this invenon in association with a pharmaceutically acceptable irrier or diluent. The compounds of this invention exibit both oral and parenteral activity and can be foriulated in dosage forms for oral, parenteral or rectal iministration.

Solid dosage forms for oral administration include ipsules, tablets, pills, powders and granules. In such )lld dosage forms, the active compound is admixed ith at least one inert diluent such as sucrose, lactose starch. Such dosage forms can also comprise, as is )rmal practice, additional substances other than inert luents; e.g., lubricating agents such as magnesium steate, and sweetening and flavoring agents. Tablets and lls can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration include \armaceutically acceptable emulsions, solutions, sus- :nsions, syrups and elixirs containing inert diluents )mmonly used in the art, such as water. Besides inert luents, such compositions can also include adjuvants, ch as wetting agents, emulsifying and suspending ;ents and sweetening, flavoring and perfuming agents. Preparations according to this invention for parenral administration include sterile aqueous or nonaleous solutions, suspensions or emulsions. Examples 'nonaqueous solvents or vehicles are propylene glyl, polyethylene glycol, vegetable oils, such as olive l, and injectable organic esters such as ethyl oleate. ch dosage forms may also contain adjuvants such as eserving, wetting, emulsifying and dispersing agents. iey may be sterilized by, for example, filtration rough a bacteria-retaining filter, by incorporating :rilizing agents into the compositions, by irradiating composition, or by heating the compositions. They n also be manufactured in the form of sterile solid mpositions which can be dissolved in sterile water or me other sterile injectable medium immediately be- 'e use.

Compositions for rectal administration are suppositos which may contain in addition to the active submce, excipients such as cocoa butter or a suppository The dosage of active ingredient in the compositions this invention may be varied; however, it is necessary it the amount of the active ingredient shall be such it a suitable dosage form is obtained. The selected sage depends upon the desired therapeutic effect, on route of administration and on the duration of the atment.

lhe following example further illustrates the pharmautical compositions which are a feature of this inven- EXAMPLE 26 lablets weighing 200 mg. and having the following mposition are prepared by standard tableting proceres:

gnesium stcuratc l It will be understood by those skilled in the art that the above composition can contain any of the compounds of this invention.

We claim:

1. A compound of the formula wherein n is 2; R and R, each are the same or different members of the group consisting of hydrogen and loweralkyl; R is loweralkyl; R is hydrogen; Y is a straight or branched chain alkylene group having from one to ten carbon atoms; and each R and R and R are the same or different members of the group consisting of loweralkenyl, hydrogen, halo, trifluoromethyl, loweralkyl, and Z is C and the pharmaceutically acceptable salts thereof.

2. A compound in accordance with claim 1 of the formula Ol'l R4 3. A compound in accordance with claim 1 of the formula 4. A compound in accordance with claim 3: lhydroxy-3-(4 p-fluorophenyll -methylbutyl )-6,6,9- trimethyl-7,8,9, l(Ltetrahydro-l-Ldibenzo[ b,d ]pyran.

5. A compound in accordance with claim 3: lhydroxy-3 -(4-phenyll -methylbutyl )-6,6,9-trimethyl- 7,8,9, 1 O-tetrahydro-GH-dibenzol b,d ]pyran.

6. A compound in accordance with claim 3: 3-( 4-p fluorophcnyl-1,Z-dimethylbutyl)-l-hydroxy-6,6,9- trimethyl-7,8,9,l(l-tctrahydro-(aH-dibenzo[b,d]pyran. 

1. A COMPOUND OF THE FORMULA
 2. A compound in accordance with claim 1 of the formula
 3. A compound in accordance with claim 1 of the formula
 4. A compound in accordance with claim 3: 1-hydroxy-3-(4-p-fluorophenyl-1-methylbutyl)-6,6,9-trimethyl-7,8,9,10 -tetrahydro-6H-dibenzo(b,d)pyran.
 5. A compound in accordance with claim 3: 1-hydroxy-3-(4-phenyl-1-methylbutyl)-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H -dibenzo(b, d)pyran.
 6. A compound in accordance with claim 3: 3-(4-p-fluorophenyl-1, 2-dimethylbutyl)-1-hydroxy-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H -dibenzo(b,d)pyran. 